Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

2018 Tecentriq (atezolizumab; Roche/Chugai) Drug Analysis: A Fully Humanized Monoclonal Antibody that Targets Programmed Death-Ligand 1 (PD-L1) -

Research and Markets
Posted on: 15 Feb 18

The "Drug Analysis: Tecentriq" drug pipelines has been added to's offering.

Tecentriq (atezolizumab; Roche/Chugai) is a fully humanized monoclonal antibody that targets programmed death-ligand 1 (PD-L1).

PD-L1 is expressed on the surface of antigen-presenting cells and some tumor cells. PD-L1 binds to programmed death-1 (PD-1) co-inhibitory receptors which are expressed on the surface of T cells after T-cell activation.

The receptor ligand interaction produces inhibitory signals which regulate T-cell activation and promote immune tolerance, which favors tumor progression. By blocking the PD-L1/PD-1 interaction, Tecentriq enables T-cell activation and allows the immune system to mount a more effective anti-tumor response.

Product Profiles

  1. Tecentriq: Prostate cancer
  2. Tecentriq: Colorectal cancer (CRC)
  3. Tecentriq: Ovarian cancer
  4. Tecentriq: Bladder cancer
  5. Tecentriq: Renal cell cancer (RCC)
  6. Tecentriq: Non-small cell lung cancer (NSCLC)
  7. atezolizumab: Breast cancer: triple-negative

For more information about this drug pipelines report visit

View source version on

Business Wire

Last updated on: 15/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.